NCT03962543 2026-04-08
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT07237100 2025-11-19
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Sutter Health
Phase 2 Recruiting
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT02101736 2023-05-24
NF105-CABO
University of Alabama at Birmingham
Phase 2 Completed
NCT00911248 2019-04-12
PTC299 for Treatment of Neurofibromatosis Type 2
PTC Therapeutics
Phase 2 Terminated
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01402817 2018-03-14
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Indiana University
Phase 2 Terminated
NCT01673009 2016-04-06
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Indiana University
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00004437 2015-03-25
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
FDA Office of Orphan Products Development
Phase 2 Completed
NCT01412892 2014-11-14
NFitor
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00754780 2012-03-19
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
Mayo Clinic
Phase 2 Completed